{"id":902543,"date":"2025-10-29T18:47:47","date_gmt":"2025-10-29T22:47:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/"},"modified":"2025-10-29T18:47:47","modified_gmt":"2025-10-29T22:47:47","slug":"heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/","title":{"rendered":"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CARY, N.C., Oct.  29, 2025  (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025.<\/p>\n<p>Mr. Cusack was appointed as a director of Heron as of October 27, 2025.\u00a0 Mr. Cusack has more than 20 years of experience in investment management and corporate finance.\u00a0 Most recently, from 2011 to 2025, he served as a Managing Director of Starboard Value LP, a New York-based investment fund with approximately $9 billion in assets under management known for its active approach to investing in public companies.\u00a0 In this capacity, Mr. Cusack played a central role in evaluating investment opportunities, developing new operating strategies, and working closely with boards and management teams to improve performance and corporate governance.\u00a0 Prior to his tenure at Starboard Value, from 2006 to 2011, he was an investment banker at Barclays Capital and Lehman Brothers focusing on Mergers &amp; Acquisitions within the Technology, Media, &amp; Telecom sectors.\u00a0 Mr. Cusack holds a B.S. in Finance &amp; Accounting from the Leonard N. Stern School of Business at New York University. \u00a0<\/p>\n<p>\u201cWe are pleased to welcome Tom to Heron\u2019s Board of Directors,\u201d said Craig Collard, Chief Executive Officer of Heron. \u201cTom will undoubtedly bring a wealth of perspective to benefit our efforts to build momentum at Heron.\u201d<\/p>\n<p>\n        <strong>About\u00a0Heron Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TkvBNre9kUYC9-_KmNoL0sXqqCHNjilirzZb42bG6xeNQXA1Wr0uM32xYu7WXn8yFd6ewlOzD_RB2jJDdv1urA==\" rel=\"nofollow\" target=\"_blank\">www.herontx.com<\/a>.<\/p>\n<p>\n        <strong>Forward-looking Statements<\/strong>\n      <\/p>\n<p>This news release contains \u201cforward-looking statements\u201d as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management\u2019s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company\u2019s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.<\/p>\n<p>\n        <strong>Investor Relations and Media Contact:<\/strong>\n      <\/p>\n<p>Ira Duarte<br \/>Executive Vice President, Chief Financial Officer<br \/>Heron Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3Xn3xF2-sMoStwBL5ELG5Qfdeq_vx1_iU9qhFp0pvJr_CBsBPqe4lSRMYXPFQiFZ4Bo82Ei0IAxUdKbc5P-xNb8dCAiZZKmaH0lPpOIrJ_Y=\" rel=\"nofollow\" target=\"_blank\">iduarte@herontx.com<\/a><br \/>858-251-4400<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDVkZGRmNjEtMDgxYi00ODk3LWExNjgtNjJkNjU3ZGJiZmVlLTEwMTkwODUtMjAyNS0xMC0yOS1lbg==\/tiny\/Heron-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.\u00a0 Mr. Cusack has more than 20 years of experience in investment management and corporate finance.\u00a0 Most recently, from 2011 to 2025, he served as a Managing Director of Starboard &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-902543","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.\u00a0 Mr. Cusack has more than 20 years of experience in investment management and corporate finance.\u00a0 Most recently, from 2011 to 2025, he served as a Managing Director of Starboard &hellip; Continue reading &quot;Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T22:47:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors\",\"datePublished\":\"2025-10-29T22:47:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/\"},\"wordCount\":469,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/\",\"name\":\"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=\",\"datePublished\":\"2025-10-29T22:47:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - Market Newsdesk","og_description":"CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.\u00a0 Mr. Cusack has more than 20 years of experience in investment management and corporate finance.\u00a0 Most recently, from 2011 to 2025, he served as a Managing Director of Starboard &hellip; Continue reading \"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-29T22:47:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors","datePublished":"2025-10-29T22:47:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/"},"wordCount":469,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/","name":"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=","datePublished":"2025-10-29T22:47:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDk2OSM3MjMzMzU5IzIwMDc1MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-announces-appointment-of-thomas-cusack-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/902543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=902543"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/902543\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=902543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=902543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=902543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}